Skip to main content

DMD

2
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Avidity Biosciences
Avidity BiosciencesCA - San Diego
1 program
1
AOC 1044Phase 21 trial
Active Trials
NCT06244082Active Not Recruiting39Est. Jul 2027
Biomed
BiomedAustralia - Sydney
1 program
1
Single dose intravenous of BBM-D101Phase 1/2
Sarepta Therapeutics
1 program
Classical conditioning taskN/A1 trial
Active Trials
NCT06581887Recruiting100Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
Avidity BiosciencesAOC 1044
Sarepta TherapeuticsClassical conditioning task

Clinical Trials (2)

Total enrollment: 139 patients across 2 trials

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

Start: Jan 2024Est. completion: Jul 202739 patients
Phase 2Active Not Recruiting
NCT06581887Sarepta TherapeuticsClassical conditioning task

Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophinopathies

Start: Sep 2022Est. completion: Dec 2024100 patients
N/ARecruiting

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 139 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.